Table 1 Characteristics of the patients at baseline
Characteristic | Nivolumab plus relatlimab (n =547) | Nivolumab (n = 546) |
|---|---|---|
Median age (range) — years | 59 (18‒89) | 59 (19‒92) |
Sex — no. (%) | ||
Male | 327 (59.8) | 315 (57.7) |
Female | 220 (40.2) | 231 (42.3) |
Geographic region — no. (%) | ||
United States/Canada | 54 (9.9) | 63 (11.5) |
Australia | 67 (12.2) | 57 (10.4) |
Europe | 318 (58.1) | 319 (58.4) |
Latin America | 76 (13.9) | 72 (13.2) |
China | 32 (5.9) | 35 (6.4) |
ECOG performance status — no. (%) | ||
0 | 494 (90.3) | 498 (91.2) |
1 | 53 (9.7) | 48 (8.8) |
AJCC stage — no. (%) | ||
IIIA−IIIB | 209 (38.2) | 199 (36.4) |
IIIC | 270 (49.4) | 271 (49.6) |
IIID−IV | 68 (12.4) | 76 (13.9) |
Melanoma subtype — no. (%) | ||
Cutaneous non-acral | 436 (79.7) | 454 (83.2) |
Cutaneous acral | 61 (11.2) | 52 (9.5) |
Mucosal | 10 (1.8) | 8 (1.5) |
Unknown primary | 38 (6.9) | 32 (5.9) |
Other | 2 (0.4) | 0 |
LDH — no. (%) | ||
≤ULN | 496 (90.7) | 486 (89.0) |
>ULN | 49 (9.0) | 57 (10.4) |
Not reported | 2 (0.4) | 3 (0.5) |
BRAF status — no. (%) | ||
Mutant | 220 (40.2) | 217 (39.7) |
Wild-type | 195 (35.6) | 200 (36.6) |
PD-L1 status — no. (%) | ||
Positive (≥1%) | 136 (24.9) | 123 (22.5) |
Negative (<1%) | 315 (57.6) | 340 (62.3) |
Indeterminate/not evaluable/not reported | 96 (17.6) | 83 (15.2) |
LAG-3 status — no. (%) | ||
Positive (≥1%) | 352 (64.4) | 352 (64.5) |
Negative (<1%) | 126 (23.0) | 145 (26.6) |
Indeterminate/not evaluable/not reported | 69 (12.6) | 49 (9.0) |
